Pyrimidina-1513-dibenzenacycloheptaphane derivative as mutant epidermal growth factor receptor inhibitor

The present invention relates to a pyrimidina-dibenzenecycloheptaphane derivative represented by chemical formula I, a solvate thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same as an active ingredient. The pyrimidina-di...

Full description

Saved in:
Bibliographic Details
Main Authors LEE SUN HOE, JEON JI YOUNG, HAN SEON YEONG, AHN YOUNG GIL, JANG SUN YOUNG
Format Patent
LanguageEnglish
Korean
Published 09.04.2021
Subjects
ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a pyrimidina-dibenzenecycloheptaphane derivative represented by chemical formula I, a solvate thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same as an active ingredient. The pyrimidina-dibenzenecycloheptaphane derivative according to the present invention can effectively inhibit growth and drug resistance of cancer cells caused by mutation of a tyrosine kinase domain of the epidermal growth factor receptor, or growth of cancer cells having such resistance. 본 발명은 하기의 화학식 I로 표시되는 피리미디나다이벤젠아사이클로헵타판 유도체, 이의 용매화물, 이의 입체 이성질체 또는 이들의 약학적으로 허용가능 한 염 및 이를 활성성분으로 함유하는 약학 조성물에 관한 것으로, 본 발명의 피리미디나다이벤젠아시클로헵타판 유도체는 상피세포 성장인자 수용체 중 티로신 키나아제 도메인의 돌연변이에 의해 유발되는 암세포의 성장 및 약물에 대한 내성, 또는 그러한 내성을 갖는 암 세포의 성장을 효과적으로 억제할 수 있다: [화학식 I] JPEGpat00011.jpg9087.
Bibliography:Application Number: KR20190121809